Invention Application
- Patent Title: PHARMACEUTICAL FORMULATIONS AND DOSAGE REGIMENS FOR MULTI-SPECIFIC BINDING PROTEINS THAT BIND HER2, NKG2D, AND CD16 FOR CANCER TREATMENT
-
Application No.: US17682367Application Date: 2022-02-28
-
Publication No.: US20220195065A1Publication Date: 2022-06-23
- Inventor: Gregory P. Chang , Ann F. Cheung , Jean-Marie Cuillerot , Daniel Fallon , Asya Grinberg , William Haney , Christopher Ryan Morgan , Michael C. Naill , Steven O'Neil , Nicolai Wagtmann , Ronnie Wei
- Applicant: Dragonfly Therapeutics, Inc.
- Applicant Address: US MA Waltham
- Assignee: Dragonfly Therapeutics, Inc.
- Current Assignee: Dragonfly Therapeutics, Inc.
- Current Assignee Address: US MA Waltham
- Main IPC: C07K16/30
- IPC: C07K16/30 ; C07K14/725 ; C07K16/28 ; C07K16/32
Abstract:
This disclosure relates to pharmaceutical formulations for multi-specific binding proteins having an epidermal growth factor receptor 2 (ErbB2 or HER2)-binding scFv, an NKG2D-binding Fab, and an antibody Fc domain. Also provided are dosage regimens for such multi-specific binding proteins and pharmaceutical formulations for use in treating cancer, such as locally advanced or metastatic solid tumor.
Information query
